Search

Your search keyword '"Garriga, J."' showing total 314 results
Start Over Author "Garriga, J." Publication Year Range Last 10 years
314 results on '"Garriga, J."'

1. Prospects for Fundamental Physics with LISA

Author

Barausse, Enrico, Berti, Emanuele, Hertog, Thomas, Hughes, Scott A., Jetzer, Philippe, Pani, Paolo, Sotiriou, Thomas P., Tamanini, Nicola, Witek, Helvi, Yagi, Kent, Yunes, Nicolas, Abdelsalhin, T., Achucarro, A., Aelst, K. V., Afshordi, N., Akcay, S., Annulli, L., Arun, K. G., Ayuso, I., Baibhav, V., Baker, T., Bantilan, H., Barreiro, T., Barrera-Hinojosa, C., Bartolo, N., Baumann, D., Belgacem, E., Bellini, E., Bellomo, N., Ben-Dayan, I., Bena, I., Benkel, R., Bergshoefs, E., Bernard, L., Bernuzzi, S., Bertacca, D., Besancon, M., Beutler, F., Beyer, F., Bhagwat, S., Bicak, J., Biondini, S., Bize, S., Blas, D., Boehmer, C., Boller, K., Bonga, B., Bonvin, C., Bosso, P., Bozzola, G., Brax, P., Breitbach, M., Brito, R., Bruni, M., Brügmann, B., Bulten, H., Buonanno, A., Burke, A. O., Burko, L. M., Burrage, C., Cabral, F., Calcagni, G., Caprini, C., Cárdenas-Avendaño, A., Celoria, M., Chatziioannou, K., Chernoff, D., Clough, K., Coates, A., Comelli, D., Compère, G., Croon, D., Cruces, D., Cusin, G., Dalang, C., Danielsson, U., Das, S., Datta, S., de Boer, J., De Luca, V., De Rham, C., Desjacques, V., Destounis, K., Di Filippo, F., Dima, A., Dimastrogiovanni, E., Dolan, S., Doneva, D., Duque, F., Durrer, R., East, W., Easther, R., Elley, M., Ellis, J. R., Emparan, R., Ezquiaga, J. M., Fairbairn, M., Fairhurst, S., Farmer, H. F., Fasiello, M. R., Ferrari, V., Ferreira, P. G., Ficarra, G., Figueras, P., Fisenko, S., Foffa, S., Franchini, N., Franciolini, G., Fransen, K., Frauendiener, J., Frusciante, N., Fujita, R., Gair, J., Ganz, A., Garcia, P., Garcia-Bellido, J., Garriga, J., Geiger, R., Geng, C., Gergely, L. Á., Germani, C., Gerosa, D., Giddings, S. B., Gourgoulhon, E., Grandclement, P., Graziani, L., Gualtieri, L., Haggard, D., Haino, S., Halburd, R., Han, W. -B., Hawken, A. J., Hees, A., Heng, I. S., Hennig, J., Herdeiro, C., Hervik, S., Holten, J. v., Hoyle, C. J. D., Hu, Y., Hull, M., Ikeda, T., Isi, M., Jenkins, A., Julié, F., Kajfasz, E., Kalaghatgi, C., Kaloper, N., Kamionkowski, M., Karas, V., Kastha, S., Keresztes, Z., Kidder, L., Kimpson, T., Klein, A., Klioner, S., Kokkotas, K., Kolesova, H., Kolkowitz, S., Kopp, J., Koyama, K., Krishnendu, N. V., Kroon, J. A. V., Kunz, M., Lahav, O., Landragin, A., Lang, R. N., Poncin-Lafitte, C. Le, Lemos, J., Li, B., Liberati, S., Liguori, M., Lin, F., Liu, G., Lobo, F. S. N., Loll, R., Lombriser, L., Lovelace, G., Macedo, R. P., Madge, E., Maggio, E., Maggiore, M., Marassi, S., Marcoccia, P., Markakis, C., Martens, W., Martinovic, K., Martins, C. J. A. P., Maselli, A., Mastrogiovanni, S., Matarrese, S., Matas, A., Mavromatos, N. E., Mazumdar, A., Meerburg, P. D., Megias, E., Miller, J., Mimoso, J. P., Mittnacht, L., Montero, M. M., Moore, B., Martin-Moruno, P., Musco, I., Nakano, H., Nampalliwar, S., Nardini, G., Nielsen, A., Novák, J., Nunes, N. J., Okounkova, M., Oliveri, R., Oppizzi, F., Orlando, G., Oshita, N., Pappas, G., Paschalidis, V., Peiris, H., Peloso, M., Perkins, S., Pettorino, V., Pikovski, I., Pilo, L., Podolsky, J., Pontzen, A., Prabhat, S., Pratten, G., Prokopec, T., Prouza, M., Qi, H., Raccanelli, A., Rajantie, A., Randall, L., Raposo, G., Raymond, V., Renaux-Petel, S., Ricciardone, A., Riotto, A., Robson, T., Roest, D., Rollo, R., Rosofsky, S., Ruan, J. J., Rubiera-García, D., Ruiz, M., Rusu, M., Sabatie, F., Sago, N., Sakellariadou, M., Saltas, I. D., Sberna, L., Sathyaprakash, B., Scheel, M., Schmidt, P., Schutz, B., Schwaller, P., Shao, L., Shapiro, S. L., Shoemaker, D., Silva, A. d., Simpson, C., Sopuerta, C. F., Spallicci, A., Stefanek, B. A., Stein, L., Stergioulas, N., Stott, M., Sutton, P., Svarc, R., Tagoshi, H., Tahamtan, T., Takeda, H., Tanaka, T., Tantilian, G., Tasinato, G., Tattersall, O., Teukolsky, S., Tiec, A. L., Theureau, G., Trodden, M., Tolley, A., Toubiana, A., Traykova, D., Tsokaros, A., Unal, C., Unnikrishnan, C. S., Vagenas, E. C., Valageas, P., Vallisneri, M., Brand, J. Van den, Broeck, C. Van den, van de Meent, M., Vanhove, P., Varma, V., Veitch, J., Vercnocke, B., Verde, L., Vernieri, D., Vernizzi, F., Vicente, R., Vidotto, F., Visser, M., Vlah, Z., Vretinaris, S., Völkel, S., Wang, Q., Wang, Yu-Tong, Werner, M. C., Westernacher, J., Weygaert, R. v. d., Wiltshire, D., Wiseman, T., Wolf, P., Wu, K., Yamada, K., Yang, H., Yi, L., Yue, X., Yvon, D., Zilhão, M., Zimmerman, A., and Zumalacarregui, M.

Subjects
General Relativity and Quantum Cosmology
Abstract

In this paper, which is of programmatic rather than quantitative nature, we aim to further delineate and sharpen the future potential of the LISA mission in the area of fundamental physics. Given the very broad range of topics that might be relevant to LISA, we present here a sample of what we view as particularly promising directions, based in part on the current research interests of the LISA scientific community in the area of fundamental physics. We organize these directions through a "science-first" approach that allows us to classify how LISA data can inform theoretical physics in a variety of areas. For each of these theoretical physics classes, we identify the sources that are currently expected to provide the principal contribution to our knowledge, and the areas that need further development. The classification presented here should not be thought of as cast in stone, but rather as a fluid framework that is amenable to change with the flow of new insights in theoretical physics., Comment: 22 pages, 1 figure, to appear in General Relativity and Gravitation

Published
2020
Full Text
View/download PDF

3. Multiple sclerosis registries in Europe – An updated mapping survey

Author

Glaser, A., Stahmann, A., Meissner, T., Flachenecker, P., Horáková, D., Zaratin, P., Brichetto, G., Pugliatti, M., Rienhoff, O., Vukusic, S., de Giacomoni, A.C., Battaglia, M.A., Brola, W., Butzkueven, H., Casey, R., Drulovic, J., Eichstädt, K., Hellwig, K., Iaffaldano, P., Ioannidou, E., Kuhle, J., Lycke, K., Magyari, M., Malbaša, T., Middleton, R., Myhr, K.M., Notas, K., Orologas, A., Otero-Romero, S., Pekmezovic, T., Sastre-Garriga, J., Seeldrayers, P., Soilu-Hänninen, M., Stawiarz, L., Trojano, M., Ziemssen, T., Hillert, J., and Thalheim, C.

Published
2019
Full Text
View/download PDF

5. Diffusion-based structural connectivity patterns of multiple sclerosis phenotypes

Author

Martinez-Heras, E, primary, Solana, E, additional, Vivó, F, additional, Lopez-Soley, E, additional, Calvi, A, additional, Alba-Arbalat, S, additional, Schoonheim, MM, additional, Strijbis, EMM, additional, Vrenken, H, additional, Barkhof, F, additional, Rocca, MA, additional, Filippi, M, additional, Pagani, E, additional, Groppa, S, additional, Fleischer, V, additional, Dineen, R, additional, Ballenberg, B, additional, Lukas, C, additional, Pareto, D, additional, Rovira, À, additional, Sastre-Garriga, J, additional, Collorone, S, additional, Prados, F, additional, Toosy, AT, additional, Ciccarelli, O, additional, Saiz, A, additional, Blanco, Y, additional, and Llufriu, S, additional

Published
2023
Full Text
View/download PDF

10. Artificial intelligence extension of the OSCAR-IB criteria

Author

Petzold, A., Albrecht, P., Balcer, L., Bekkers, E., Brandt, A. U., Calabresi, P. A., Deborah, O. G., Graves, J. S., Green, A., Keane, P. A., Nij Bijvank, J. A., Sander, J. W., Paul, F., Saidha, S., Villoslada, P., Wagner, S. K., Yeh, E. A., Aktas, O., Antel, J., Asgari, N., Audo, I., Avasarala, J., Avril, D., Bagnato, F. R., Banwell, B., Bar-Or, A., Behbehani, R., Manterola, A. B., Bennett, J., Benson, L., Bernard, J., Bremond-Gignac, D., Britze, J., Burton, J., Calkwood, J., Carroll, W., Chandratheva, A., Cohen, J., Comi, G., Cordano, C., Costa, S., Costello, F., Courtney, A., Cruz-Herranz, A., Cutter, G., Crabb, D., Delott, L., De Seze, J., Diem, R., Dollfuss, H., El Ayoubi, N. K., Fasser, C., Finke, C., Fischer, D., Fitzgerald, K., Fonseca, P., Frederiksen, J. L., Frohman, E., Frohman, T., Fujihara, K., Cuellar, I. G., Galetta, S., Garcia-Martin, E., Giovannoni, G., Glebauskiene, B., Suarez, I. G., Jensen, G. P., Hamann, S., Hartung, H. -P., Havla, J., Hemmer, B., Huang, S. -C., Imitola, J., Jasinskas, V., Jiang, H., Kafieh, R., Kappos, L., Kardon, R., Keegan, D., Kildebeck, E., Kim, U. S., Klistorner, S., Knier, B., Kolbe, S., Korn, T., Krupp, L., Lagreze, W., Leocani, L., Levin, N., Liskova, P., Preiningerova, J. L., Lorenz, B., May, E., Miller, D., Mikolajczak, J., Said, S. M., Montalban, X., Morrow, M., Mowry, E., Murta, J., Navas, C., Nolan, R., Nowomiejska, K., Oertel, F. C., Oh, J., Oreja-Guevara, C., Orssaud, C., Osborne, B., Outteryck, O., Paiva, C., Palace, J., Papadopoulou, A., Patsopoulos, N., Pontikos, N., Preising, M., Prince, J., Reich, D., Rejdak, R., Ringelstein, M., Rodriguez de Antonio, L., Sahel, J. -A., Sanchez-Dalmau, B., Sastre-Garriga, J., Schippling, S., Schuman, J., Shindler, K., Shin, R., Shuey, N., Soelberg, K., Specovius, S., Suppiej, A., Thompson, A., Toosy, A., Torres, R., Touitou, V., Trauzettel-Klosinski, S., van der Walt, A., Vermersch, P., Vidal-Jordana, A., Waldman, A. T., Waters, C., Wheeler, R., White, O., Wilhelm, H., Winges, K. M., Wiegerinck, N., Wiehe, L., Wisnewski, T., Wong, S., Wurfel, J., Yaghi, S., You, Y., Yu, Z., Yu-Wai-Man, P., Zemaitien≐, R., Zimmermann, H., Albrecht P., Petzold A., Balcer, L., Bekkers, E., Brandt, A. U., Calabresi, P. A., Deborah, O. G., Graves, J. S., Green, A., Keane, P. A., Nij Bijvank, J. A., Sander, J. W., Paul, F., Saidha, S., Villoslada, P., Wagner, S. K., Yeh, E. A., Aktas, O., Antel, J., Asgari, N., Audo, I., Avasarala, J., Avril, D., Bagnato, F. R., Banwell, B., Bar-Or, A., Behbehani, R., Manterola, A. B., Bennett, J., Benson, L., Bernard, J., Bremond-Gignac, D., Britze, J., Burton, J., Calkwood, J., Carroll, W., Chandratheva, A., Cohen, J., Comi, G., Cordano, C., Costa, S., Costello, F., Courtney, A., Cruz-Herranz, A., Cutter, G., Crabb, D., Delott, L., De Seze, J., Diem, R., Dollfuss, H., El Ayoubi, N. K., Fasser, C., Finke, C., Fischer, D., Fitzgerald, K., Fonseca, P., Frederiksen, J. L., Frohman, E., Frohman, T., Fujihara, K., Cuellar, I. G., Galetta, S., Garcia-Martin, E., Giovannoni, G., Glebauskiene, B., Suarez, I. G., P. , Jensen, G., Hamann, S., Hartung, H. -P., Havla, J., Hemmer, B., Huang, S. -C., Imitola, J., Jasinskas, V., Jiang, H., Kafieh, R., Kappos, L., Kardon, R., Keegan, D., Kildebeck, E., Kim, U. S., Klistorner, S., Knier, B., Kolbe, S., Korn, T., Krupp, L., Lagreze, W., Leocani, L., Levin, N., Liskova, P., Preiningerova, J. L., Lorenz, B., May, E., Miller, D., Mikolajczak, J., Said, S. M., Montalban, X., Morrow, M., Mowry, E., Murta, J., Navas, C., Nolan, R., Nowomiejska, K., Oertel, F. C., Oh, J., Oreja-Guevara, C., Orssaud, C., Osborne, B., Outteryck, O., Paiva, C., Palace, J., Papadopoulou, A., Patsopoulos, N., Pontikos, N., Preising, M., Prince, J., Reich, D., Rejdak, R., Ringelstein, M., Rodriguez de Antonio, L., Sahel, J. -A., Sanchez-Dalmau, B., Sastre-Garriga, J., Schippling, S., Schuman, J., Shindler, K., Shin, R., Shuey, N., Soelberg, K., Specovius, S., Suppiej, A., Thompson, A., Toosy, A., Torres, R., Touitou, V., Trauzettel-Klosinski, S., van der Walt, A., Vermersch, P., Vidal-Jordana, A., Waldman, A. T., Waters, C., Wheeler, R., White, O., Wilhelm, H., Winges, K. M., Wiegerinck, N., Wiehe, L., Wisnewski, T., Wong, S., Wurfel, J., Yaghi, S., You, Y., Yu, Z., Yu-Wai-Man, P., Zemaitien≐, R., and Zimmermann, H.

Subjects
0301 basic medicine, Big Data, medicine.medical_specialty, Neurology, media_common.quotation_subject, Big data, MEDLINE, Reviews, Socio-culturale, Neurosciences. Biological psychiatry. Neuropsychiatry, Review, Public domain, Retina, Cohort Studies, 03 medical and health sciences, Annotation, 0302 clinical medicine, Artificial Intelligence, medicine, Humans, Quality (business), RC346-429, Tomography, media_common, Image pattern recognition, business.industry, General Neuroscience, Nervous System Diseases, Tomography, Optical Coherence, Algorithms, 030104 developmental biology, Optical Coherence, Imaging technology, RC0321, Neurology. Diseases of the nervous system, Neurology (clinical), Artificial intelligence, sense organs, business, 030217 neurology & neurosurgery, RC321-571
Abstract

Artificial intelligence (AI)‐based diagnostic algorithms have achieved ambitious aims through automated image pattern recognition. For neurological disorders, this includes neurodegeneration and inflammation. Scalable imaging technology for big data in neurology is optical coherence tomography (OCT). We highlight that OCT changes observed in the retina, as a window to the brain, are small, requiring rigorous quality control pipelines. There are existing tools for this purpose. Firstly, there are human‐led validated consensus quality control criteria (OSCAR‐IB) for OCT. Secondly, these criteria are embedded into OCT reporting guidelines (APOSTEL). The use of the described annotation of failed OCT scans advances machine learning. This is illustrated through the present review of the advantages and disadvantages of AI‐based applications to OCT data. The neurological conditions reviewed here for the use of big data include Alzheimer disease, stroke, multiple sclerosis (MS), Parkinson disease, and epilepsy. It is noted that while big data is relevant for AI, ownership is complex. For this reason, we also reached out to involve representatives from patient organizations and the public domain in addition to clinical and research centers. The evidence reviewed can be grouped in a five‐point expansion of the OSCAR‐IB criteria to embrace AI (OSCAR‐AI). The review concludes by specific recommendations on how this can be achieved practically and in compliance with existing guidelines.

Published
2021

11. Expert-Agreed Practical Recommendations on the Use of Cladribine

Author

Meca-Lallana V, García Domínguez JM, López Ruiz R, Martín-Martínez J, Arés Luque A, Hernández Pérez MA, Prieto González JM, Landete Pascual L, and Sastre-Garriga J

Subjects
Consensus, Expert opinion, Relapsing multiple sclerosis, Cladribine, Disease-modifying drugs, Treatment response
Abstract

Cladribine is a disease-modifying selective immune reconstitution oral therapy for adult patients with highly active relapsing multiple sclerosis (RMS). It was approved in the USA in 2019 and in Europe in 2017, thus there are still gaps in existing guidelines for using cladribine tablets in clinical practice. Nine experts with extensive experience in managing patients with multiple sclerosis in Spain identified some of the unanswered questions related to the real-life use of cladribine tablets. They reviewed the available clinical trial data and real-world evidence, including their own experiences of using cladribine, over the course of three virtual meetings held between November 2020 and January 2021. This article gathers their practical recommendations to aid treatment decision-making and optimise the use of cladribine tablets in patients with RMS. The consensus recommendations cover the following areas: candidate patient profiles, switching strategies (to and from cladribine), managing response to cladribine and safety considerations.

Published
2022

12. The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease

Author

Geraldes, R., Jurynczyk, M., dos Passos, G. R., Pichler, A., Chung, K., Hagens, M., Ruggieri, S., Auger, C., Sastre-Garriga, J., Enzinger, C., Chard, D., Barkhof, F., Gasperini, C., Rovira, A., DeLuca, G., Palace, J., MAGNIMS Study, Group, Filippi, M., Rocca, M. A., Institut Català de la Salut, [Geraldes R, Juryńczyk M, Rodrigues dos Passos G] Nuffield Department of Clinical Neurosciences, Oxford, UK. [Pichler A] Department of Neurology, Medical University of Graz, Graz, Austria/Division of Neuroradiology, Vascular & Interventional Radiology, Medical University of Graz, Graz, Austria. [Chung K] NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London Institute of Neurology, London, UK. [Hagens M] MS Center Amsterdam, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. [Auger C, Rovira A] Secció de Neuroradiologia, Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sastre-Garriga J] Servei de Neurologia/ Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Neurology, Amsterdam Neuroscience - Neuroinfection & -inflammation, Amsterdam Neuroscience - Brain Imaging, Radiology and nuclear medicine, Geraldes, R., Jurynczyk, M., dos Passos, G. R., Pichler, A., Chung, K., Hagens, M., Ruggieri, S., Auger, C., Sastre-Garriga, J., Enzinger, C., Chard, D., Barkhof, F., Gasperini, C., Rovira, A., Deluca, G., Palace, J., MAGNIMS Study, Group, Filippi, M., and Rocca, M. A.

Subjects
medicine.medical_specialty, cerebral small vessel disease, differential diagnosis, imaging, Multiple sclerosis, Esclerosi múltiple, Disease, Vascular risk, Cervell - Vasos sanguinis - Malalties, Lesion, 03 medical and health sciences, 0302 clinical medicine, Short Reports, Risk Factors, Internal medicine, Pons, Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos cerebrovasculares::enfermedades de los pequeños vasos cerebrales [ENFERMEDADES], Medicine, Humans, diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], 030304 developmental biology, 0303 health sciences, Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Cerebral Small Vessel Diseases [DISEASES], business.industry, Brain, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], medicine.disease, Magnetic Resonance Imaging, Neurology, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Cardiology, Imatgeria per ressonància magnètica, Neurology (clinical), Small vessel, Differential diagnosis, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract

Esclerosi múltiple; Diagnòstic diferencial; Imatges Esclerosis múltiple; Diagnóstico diferencial; Imagen Multiple sclerosis; Differential diagnosis; Imaging Background: Differentiating multiple sclerosis (MS) from vascular risk factor (VRF)-small vessel disease (SVD) can be challenging. Objective and Methods: In order to determine whether or not pontine lesion location is a useful discriminator of MS and VRF-SVD, we classified pontine lesions on brain magnetic resonance imaging (MRI) as central or peripheral in 93 MS cases without VRF, 108 MS patients with VRF and 43 non-MS cases with VRF. Results: MS without VRF were more likely to have peripheral pons lesions (31.2%, 29/93) than non-MS with VRF (0%, 0/43) (Exp(B) = 29.8; 95% confidence interval (CI) = (1.98, 448.3); p = 0.014) but there were no significant differences regarding central pons lesions between MS without VRF (5.4%, 5/93) and non-MS with VRF patients (16.3%, 7/43) (Exp(B) = 0.89; 95% CI = (0.2, 3.94); p = 0.87). The presence of peripheral pons lesions discriminated between MS and VRF-SVD with 100% (95% CI = (91.8, 100)) specificity. The proportion of peripheral pons lesions in MS with VRF (30.5%, 33/108) was similar to that seen in MS without VRF (31.2%, 29/93, p = 0.99). Central lesions occurred in similar frequency in MS with VRF (8.3%, 9/108) and non-MS with VRF (16.3%, 7/43, p = 0.15). Conclusion: Peripheral pons lesion location is a good discriminator of MS from vascular lesions. The author(s) received no financial support for the research, authorship and/or publication of this article.

Published
2020

16. Optical coherence tomography in multiple sclerosis: a 3-year prospective multicenter study

Author

Paul, F., Calabresi, P.A., Barkhof, F., Green, A.J., Kardon, R., Sastre-Garriga, J., Schippling, S., Vermersch, P., Saidha, S., Gerendas, B.S., Schmidt-Erfurth, U., Agoropoulou, C., Zhang, Y., Seifer, G., and Petzold, A.

Subjects
genetic structures, sense organs, Function and Dysfunction of the Nervous System
Abstract

OBJECTIVE: To evaluate changes over 3 years in the thickness of inner retinal layers including the peripapillary retinal nerve fiber layer (pRNFL), and combined macular ganglion cell and inner plexiform layers (mGCIPL), in individuals with relapsing-remitting multiple sclerosis (RRMS) versus healthy controls; to determine whether optical coherence tomography (OCT) is sufficiently sensitive and reproducible to detect small degrees of neuroaxonal loss over time that correlate with changes in brain volume and disability progression as measured by the Expanded Disability Status Scale (EDSS). METHODS: Individuals with RRMS from 28 centers (n = 333) were matched with 64 healthy participants. OCT scans were performed on Heidelberg Spectralis machines (at baseline; 1 month; 6 months; 6-monthly thereafter). RESULTS: OCT measurements were highly reproducible between baseline and 1 month (intraclass correlation coefficient >0.98). Significant inner retinal layer thinning was observed in individuals with multiple sclerosis (MS) compared with controls regardless of previous MS-associated optic neuritis--group differences (95% CI) over 3 years: pRNFL: -1.86 (-2.54, -1.17) µm; mGCIPL: -2.03 (-2.78, -1.28) µm (both p 5 years (pRNFL: p

Published
2021

17. P.048 International MAGNIMS-CMSC-NAIMS consensus recommendations on the use of standardized MRI in MS

Author

Traboulsee, A, primary, Wattjes, M, additional, Ciccarelli, O, additional, Reich, D, additional, Banwell, B, additional, de Stefano, N, additional, Enzinger, C, additional, Fazekas, F, additional, Filippi, M, additional, Frederiksen, J, additional, Gasperini, C, additional, Hacohen, Y, additional, Kappos, L, additional, Li, DK, additional, Mankad, K, additional, Montalban, X, additional, Newsome, S, additional, Oh, J, additional, Palace, J, additional, Rocca, M, additional, Sastre-Garriga, J, additional, Tintore, M, additional, Vrenken, H, additional, Yours, T, additional, Barkhof, F, additional, and Rovira, A, additional

Published
2021
Full Text
View/download PDF

18. Mind the gap: from neurons to networks to outcomes in multiple sclerosis

Author

Chard, D. T., Alahmadi, A. A. S., Audoin, B., Charalambous, T., Enzinger, C., Hulst, H. E., Rocca, M. A., Rovira, A., Sastre-Garriga, J., Schoonheim, M. M., Tijms, B., Tur, C., Gandini Wheeler-Kingshott, C. A. M., Wink, A. M., Ciccarelli, O., Barkhof, F., De Stefano, N., Filippi, M., Frederiksen, J. L., Gasperini, C., Kappos, L., Palace, J., Yousry, T., Vrenken, H., University College of London [London] (UCL), Department of Diagnostic Radiology, Faculty of Applied Medical Science, King Abdulaziz University (KAU), Jeddah, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - APHM] (CEMEREM), Hôpital de la Timone [CHU - APHM] (TIMONE)-Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), AP-HM, CHU Timone, Pole de Neurosciences Cliniques, Department of Neurology, Marseille, France., Department of Neurology, Research Unit for Neuronal Repair and Plasticity, Medical University of Graz, Graz, Department of Radiology, Division of Neuroradiology, Vascular and Interventional Radiology, Medical University of Graz, Graz, Department of Anatomy and Neurosciences, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Neuroimaging Research Unit and Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Universitat Autònoma de Barcelona (UAB), Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Department of Neurology, Luton and Dunstable University Hospital, Luton, Università degli Studi di Pavia = University of Pavia (UNIPV), Brain MRI 3T Research Center, IRCCS Mondino Foundation, Pavia, Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London, Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - AP-HM] (CEMEREM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)- Hôpital de la Timone [CHU - APHM] (TIMONE), Section of Neuroradiology, Department of Radiology Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Institutes of Neurology and Healthcare Engineering, University College London, London, Chard, Declan T, Alahmadi, Adnan A S, Audoin, Bertrand, Charalambous, Thali, Enzinger, Christian, Hulst, Hanneke E, Rocca, Maria A, Rovira, Àlex, Sastre-Garriga, Jaume, Schoonheim, Menno M, Tijms, Betty, Tur, Carmen, Gandini Wheeler-Kingshott, Claudia A M, Wink, Alle Meije, Ciccarelli, Olga, Barkhof, Frederik, MAGNIMS Study, Group, and Filippi, Massimo

Subjects
Multiple Sclerosis, Grey matter, Network topology, 030218 nuclear medicine & medical imaging, White matter, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Alzheimer Disease, medicine, Humans, Default mode network, ComputingMilieux_MISCELLANEOUS, Inflammation, Neurons, Artificial neural network, business.industry, Multiple sclerosis, [SCCO.NEUR]Cognitive science/Neuroscience, Brain, medicine.disease, medicine.anatomical_structure, Neurology (clinical), Disconnection, Alzheimer's disease, Nerve Net, business, Neuroscience, 030217 neurology & neurosurgery
Abstract

MRI studies have provided valuable insights into the structure and function of neural networks, particularly in health and in classical neurodegenerative conditions such as Alzheimer disease. However, such work is also highly relevant in other diseases of the CNS, including multiple sclerosis (MS). In this Review, we consider the effects of MS pathology on brain networks, as assessed using MRI, and how these changes to brain networks translate into clinical impairments. We also discuss how this knowledge can inform the targeting of MS treatments and the potential future directions for research in this area. Studying MS is challenging as its pathology involves neurodegenerative and focal inflammatory elements, both of which could disrupt neural networks. The disruption of white matter tracts in MS is reflected in changes in network efficiency, an increasingly random grey matter network topology, relative cortical disconnection, and both increases and decreases in connectivity centred around hubs such as the thalamus and the default mode network. The results of initial longitudinal studies suggest that these changes evolve rather than simply increase over time and are linked with clinical features. Studies have also identified a potential role for treatments that functionally modify neural networks as opposed to altering their structure.

Published
2021

19. Transperineal anal sphincter complex evaluation after obstetric anal sphincter injuries: With or without tomographic ultrasound imaging technique?

Author

Martínez Franco E, Ros C, Santoro GA, Cassadó Garriga J, Amat Tardiu L, Cuadras-Palleja D, and Espuña M

Subjects
Anal sphincter, OASIS, Tomographic ultrasound imaging, Transperineal ultrasound
Abstract

OBJECTIVES: "Significant" obstetric anal sphincter injuries (OASIS) have been defined as visible defects of at least 30° in at least 4/6 slices using tomographic ultrasound imaging (TUI) with transperineal ultrasound (TPUS). The objective of this study was to assess if TUI is mandatory for the evaluation of OASIS. METHODS: Patients with a history of OASIS were evaluated by performing 3D-endoanal ultrasound (EAUS) and 3D-TPUS with and without TUI. Any damage to the internal (IAS) or external (EAS) anal sphincters was recorded and scored using the Starck's and the Norderval's systems. Intraobserver and inter-techniques correlations were calculated. RESULTS: From September 2012 to May 2015, 63 women, mean age 32.5 ± 4.6 years, with OASIS (3a: 26 pts., 41.3 %; 3b: 26 pts., 41.3 %; 3c: 6 pts., 9.5 %, 4: 4 pts., 6.3 %, "button hole" tear: 1 pt., 1.6 %). Inter-technique and intraobserver correlations were excellent (TUI: k = 0.9; sweeping technique: k = 0.85; EAUS: k = 0.9) in determining OASIS. Using the Starck's Score, excellent correlation was found for both TPUS modalities (TUI: k = 0.86; sweeping technique: k = 0.89). However, for the different individual parameters, the correlation was moderate for EAS depth (TUI: k = 0.44; sweeping technique: k = 0.5) and good for IAS depth (TUI: k = 0.7; sweeping technique: k = 0.78). Similar results were found using the Norderval's classification. CONCLUSIONS: OASIS can be assessed by TPUS without TUI technique, dragging the rendered box and following the anal canal from the anal verge to the anorectal junction in the longitudinal plane and describing findings.

Published
2021

21. Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging

Author

Storelli, L, Rocca, M, Pagani, E, Van Hecke, W, Horsfield, M, De Stefano, N, Rovira, A, Sastre-Garriga, J, Palace, J, Sima, D, Smeets, D, Filippi, M, Group, Magnims Study, Storelli, Loredana, Rocca, Maria A., Pagani, Elisabetta, Van Hecke, Wim, Horsfield, Mark A., De Stefano, Nicola, Rovira, Alex, Sastre-Garriga, Jaume, Palace, Jacqueline, Sima, Diana, Smeets, Dirk, and Filippi, Massimo

Subjects
Adult, Male, Radiology, Nuclear Medicine and Imaging, medicine.medical_specialty, Multiple Sclerosis, Reproducibility of Result, Gray (unit), 030218 nuclear medicine & medical imaging, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Software, Atrophy, Multiple Sclerosi, Image Processing, Computer-Assisted, medicine, Humans, Radiology, Nuclear Medicine and imaging, Gray Matter, Cross-Sectional Studie, business.industry, Multiple sclerosis, Reproducibility of Results, Brain, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Mr imaging, Cross-Sectional Studies, Female, Radiology, business, 030217 neurology & neurosurgery, Human
Abstract

Purpose To compare available methods for whole-brain and gray matter (GM) atrophy estimation in multiple sclerosis (MS) in terms of repeatability (same magnetic resonance [MR] imaging unit) and reproducibility (different system/field strength) for their potential clinical applications. Materials and Methods The softwares ANTs-v1.9, CIVET-v2.1, FSL-SIENAX/SIENA-5.0.1, Icometrix-MSmetrix-1.7, and SPM-v12 were compared. This retrospective study, performed between March 2015 and March 2017, collected data from (a) eight simulated MR images and longitudinal data (2 weeks) from 10 healthy control subjects to assess the cross-sectional and longitudinal accuracy of atrophy measures, (b) test-retest MR images in 29 patients with MS acquired within the same day at different imaging unit field strengths/manufacturers to evaluate precision, and (c) longitudinal data (1 year) in 24 patients with MS for the agreement between methods. Tissue segmentation, image registration, and white matter (WM) lesion filling were also evaluated. Multiple paired t tests were used for comparisons. Results High values of accuracy (0.87-0.97) for whole-brain and GM volumes were found, with the lowest values for MSmetrix. ANTs showed the lowest mean error (0.02%) for whole-brain atrophy in healthy control subjects, with a coefficient of variation of 0.5%. SPM showed the smallest mean error (0.07%) and coefficient of variation (0.08%) for GM atrophy. Globally, good repeatability (P > .05) but poor reproducibility (P < .05) were found for all methods. WM lesion filling technique mainly affected ANTs, MSmetrix, and SPM results (P < .05). Conclusion From this comparison, it would be possible to select a software for atrophy measurement, depending on the requirements of the application (research center, clinical trial) and its goal (accuracy and repeatability or reproducibility). An improved reproducibility is required for clinical application. © RSNA, 2018 Online supplemental material is available for this article.

Published
2018

22. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI

Author

Amiri, Houshang, de Sitter, Alexandra, Bendfeldt, Kerstin, Battaglini, Marco, Gandini Wheeler-Kingshott, Claudia A M, Calabrese, Massimiliano, Geurts, Jeroen J G, Rocca, Maria A, Sastre-Garriga, Jaume, Enzinger, Christian, de Stefano, Nicola, Filippi, Massimo, Rovira, Álex, Barkhof, Frederik, Vrenken, Hugo, Barkhof, F, Vrenken, H, Ciccarelli, O, Fredriksen, J L, Palace, J, Rovira, A, Sastre-Garriga, J, Amiri, Houshang, de Sitter, Alexandra, Bendfeldt, Kerstin, Battaglini, Marco, Gandini Wheeler-Kingshott, Claudia A. M., Calabrese, Massimiliano, Geurts, Jeroen J. G., Rocca, Maria A., Sastre-Garriga, Jaume, Enzinger, Christian, de Stefano, Nicola, Filippi, Massimo, Rovira, Álex, Barkhof, Frederik, and Vrenken, Hugo

Subjects
Radiology, Nuclear Medicine and Imaging, Brain atrophy, TR, Neurology, White Matter/pathology, CTh, brain extraction tool, lcsh:RC346-429, Magnetic Resonance Imaging/methods, 030218 nuclear medicine & medical imaging, deep grey matter, 0302 clinical medicine, Nuclear Medicine and Imaging, TI, inversion time, FA, fractional anisotropy, Gray Matter, repetition time, VBM, TE, echo time, Brain Mapping, medicine.diagnostic_test, Grey matter atrophy, DGM, Regular Article, GM, CTh, cortical thickness, Multiple Sclerosis/pathology, diffusion tensor imaging, Magnetic Resonance Imaging, White Matter, TR, repetition time, medicine.anatomical_structure, DTI, lcsh:R858-859.7, CNS, TI, Radiology, fractional anisotropy, MRI, TE, FA, inversion time, medicine.medical_specialty, Grey matter, Multiple Sclerosis, Cognitive Neuroscience, Cognitive neuroscience, Gray Matter/pathology, lcsh:Computer applications to medicine. Medical informatics, CNS, central nervous system, echo time, MS, multiple sclerosis, Multiple sclerosis, VBM, voxel-based morphometry, 03 medical and health sciences, Magnetic resonance imaging, Atrophy, BET, brain extraction tool, DGM, deep grey matter, DTI, diffusion tensor imaging, GM, grey matter, MRI, magnetic resonance imaging, WM, white matter, medicine, voxel-based morphometry, Humans, Multiple sclerosi, Radiology, Nuclear Medicine and imaging, WM, Intensive care medicine, lcsh:Neurology. Diseases of the nervous system, business.industry, MS, cortical thickness, BET, central nervous system, medicine.disease, Atrophy/pathology, Neurology (clinical), Clinical trial, business, 030217 neurology & neurosurgery
Abstract

Atrophy of the brain grey matter (GM) is an accepted and important feature of multiple sclerosis (MS). However, its accurate measurement is hampered by various technical, pathological and physiological factors. As a consequence, it is challenging to investigate the role of GM atrophy in the disease process as well as the effect of treatments that aim to reduce neurodegeneration. In this paper we discuss the most important challenges currently hampering the measurement and interpretation of GM atrophy in MS. The focus is on measurements that are obtained in individual patients rather than on group analysis methods, because of their importance in clinical trials and ultimately in clinical care. We discuss the sources and possible solutions of the current challenges, and provide recommendations to achieve reliable measurement and interpretation of brain GM atrophy in MS., Highlights • Accurate measurement of brain GM atrophy in MS is hampered by various physiological, pathological and technical factors. • Challenges to achieve accuracy in quantification and interpretation of atrophy in MS are discussed. • Recommendations on how to achieve reliable measurement and interpretation of GM atrophy in MS are suggested.

Published
2018

23. Prospects for fundamental physics with LISA

Author

Barausse, Enrico, primary, Berti, Emanuele, additional, Hertog, Thomas, additional, Hughes, Scott A., additional, Jetzer, Philippe, additional, Pani, Paolo, additional, Sotiriou, Thomas P., additional, Tamanini, Nicola, additional, Witek, Helvi, additional, Yagi, Kent, additional, Yunes, Nicolás, additional, Abdelsalhin, T., additional, Achucarro, A., additional, van Aelst, K., additional, Afshordi, N., additional, Akcay, S., additional, Annulli, L., additional, Arun, K. G., additional, Ayuso, I., additional, Baibhav, V., additional, Baker, T., additional, Bantilan, H., additional, Barreiro, T., additional, Barrera-Hinojosa, C., additional, Bartolo, N., additional, Baumann, D., additional, Belgacem, E., additional, Bellini, E., additional, Bellomo, N., additional, Ben-Dayan, I., additional, Bena, I., additional, Benkel, R., additional, Bergshoefs, E., additional, Bernard, L., additional, Bernuzzi, S., additional, Bertacca, D., additional, Besancon, M., additional, Beutler, F., additional, Beyer, F., additional, Bhagwat, S., additional, Bicak, J., additional, Biondini, S., additional, Bize, S., additional, Blas, D., additional, Boehmer, C., additional, Boller, K., additional, Bonga, B., additional, Bonvin, C., additional, Bosso, P., additional, Bozzola, G., additional, Brax, P., additional, Breitbach, M., additional, Brito, R., additional, Bruni, M., additional, Brügmann, B., additional, Bulten, H., additional, Buonanno, A., additional, Burko, L. M., additional, Burrage, C., additional, Cabral, F., additional, Calcagni, G., additional, Caprini, C., additional, Cárdenas-Avendaño, A., additional, Celoria, M., additional, Chatziioannou, K., additional, Chernoff, D., additional, Clough, K., additional, Coates, A., additional, Comelli, D., additional, Compère, G., additional, Croon, D., additional, Cruces, D., additional, Cusin, G., additional, Dalang, C., additional, Danielsson, U., additional, Das, S., additional, Datta, S., additional, de Boer, J., additional, De Luca, V., additional, De Rham, C., additional, Desjacques, V., additional, Destounis, K., additional, Filippo, F. Di, additional, Dima, A., additional, Dimastrogiovanni, E., additional, Dolan, S., additional, Doneva, D., additional, Duque, F., additional, Durrer, R., additional, East, W., additional, Easther, R., additional, Elley, M., additional, Ellis, J. R., additional, Emparan, R., additional, Ezquiaga, J. M., additional, Fairbairn, M., additional, Fairhurst, S., additional, Farmer, H. F., additional, Fasiello, M. R., additional, Ferrari, V., additional, Ferreira, P. G., additional, Ficarra, G., additional, Figueras, P., additional, Fisenko, S., additional, Foffa, S., additional, Franchini, N., additional, Franciolini, G., additional, Fransen, K., additional, Frauendiener, J., additional, Frusciante, N., additional, Fujita, R., additional, Gair, J., additional, Ganz, A., additional, Garcia, P., additional, Garcia-Bellido, J., additional, Garriga, J., additional, Geiger, R., additional, Geng, C., additional, Gergely, L. Á., additional, Germani, C., additional, Gerosa, D., additional, Giddings, S. B., additional, Gourgoulhon, E., additional, Grandclement, P., additional, Graziani, L., additional, Gualtieri, L., additional, Haggard, D., additional, Haino, S., additional, Halburd, R., additional, Han, W.-B., additional, Hawken, A. J., additional, Hees, A., additional, Heng, I. S., additional, Hennig, J., additional, Herdeiro, C., additional, Hervik, S., additional, Holten, J. v., additional, Hoyle, C. J. D., additional, Hu, Y., additional, Hull, M., additional, Ikeda, T., additional, Isi, M., additional, Jenkins, A., additional, Julié, F., additional, Kajfasz, E., additional, Kalaghatgi, C., additional, Kaloper, N., additional, Kamionkowski, M., additional, Karas, V., additional, Kastha, S., additional, Keresztes, Z., additional, Kidder, L., additional, Kimpson, T., additional, Klein, A., additional, Klioner, S., additional, Kokkotas, K., additional, Kolesova, H., additional, Kolkowitz, S., additional, Kopp, J., additional, Koyama, K., additional, Krishnendu, N. V., additional, Kroon, J. A. V., additional, Kunz, M., additional, Lahav, O., additional, Landragin, A., additional, Lang, R. N., additional, Poncin-Lafitte, C. Le, additional, Lemos, J., additional, Li, B., additional, Liberati, S., additional, Liguori, M., additional, Lin, F., additional, Liu, G., additional, Lobo, F. S. N., additional, Loll, R., additional, Lombriser, L., additional, Lovelace, G., additional, Macedo, R. P., additional, Madge, E., additional, Maggio, E., additional, Maggiore, M., additional, Marassi, S., additional, Marcoccia, P., additional, Markakis, C., additional, Martens, W., additional, Martinovic, K., additional, Martins, C. J. A. P., additional, Maselli, A., additional, Mastrogiovanni, S., additional, Matarrese, S., additional, Matas, A., additional, Mavromatos, N. E., additional, Mazumdar, A., additional, Meerburg, P. D., additional, Megias, E., additional, Miller, J., additional, Mimoso, J. P., additional, Mittnacht, L., additional, Montero, M. M., additional, Moore, B., additional, Martin-Moruno, P., additional, Musco, I., additional, Nakano, H., additional, Nampalliwar, S., additional, Nardini, G., additional, Nielsen, A., additional, Novák, J., additional, Nunes, N. J., additional, Okounkova, M., additional, Oliveri, R., additional, Oppizzi, F., additional, Orlando, G., additional, Oshita, N., additional, Pappas, G., additional, Paschalidis, V., additional, Peiris, H., additional, Peloso, M., additional, Perkins, S., additional, Pettorino, V., additional, Pikovski, I., additional, Pilo, L., additional, Podolsky, J., additional, Pontzen, A., additional, Prabhat, S., additional, Pratten, G., additional, Prokopec, T., additional, Prouza, M., additional, Qi, H., additional, Raccanelli, A., additional, Rajantie, A., additional, Randall, L., additional, Raposo, G., additional, Raymond, V., additional, Renaux-Petel, S., additional, Ricciardone, A., additional, Riotto, A., additional, Robson, T., additional, Roest, D., additional, Rollo, R., additional, Rosofsky, S., additional, Ruan, J. J., additional, Rubiera-García, D., additional, Ruiz, M., additional, Rusu, M., additional, Sabatie, F., additional, Sago, N., additional, Sakellariadou, M., additional, Saltas, I. D., additional, Sberna, L., additional, Sathyaprakash, B., additional, Scheel, M., additional, Schmidt, P., additional, Schutz, B., additional, Schwaller, P., additional, Shao, L., additional, Shapiro, S. L., additional, Shoemaker, D., additional, Silva, A. d., additional, Simpson, C., additional, Sopuerta, C. F., additional, Spallicci, A., additional, Stefanek, B. A., additional, Stein, L., additional, Stergioulas, N., additional, Stott, M., additional, Sutton, P., additional, Svarc, R., additional, Tagoshi, H., additional, Tahamtan, T., additional, Takeda, H., additional, Tanaka, T., additional, Tantilian, G., additional, Tasinato, G., additional, Tattersall, O., additional, Teukolsky, S., additional, Tiec, A. L., additional, Theureau, G., additional, Trodden, M., additional, Tolley, A., additional, Toubiana, A., additional, Traykova, D., additional, Tsokaros, A., additional, Unal, C., additional, Unnikrishnan, C. S., additional, Vagenas, E. C., additional, Valageas, P., additional, Vallisneri, M., additional, Brand, J. Van den, additional, Broeck, C. Van den, additional, de Meent, M. van, additional, Vanhove, P., additional, Varma, V., additional, Veitch, J., additional, Vercnocke, B., additional, Verde, L., additional, Vernieri, D., additional, Vernizzi, F., additional, Vicente, R., additional, Vidotto, F., additional, Visser, M., additional, Vlah, Z., additional, Vretinaris, S., additional, Völkel, S., additional, Wang, Q., additional, Wang, Yu-Tong, additional, Werner, M. C., additional, Westernacher, J., additional, Weygaert, R. v. d., additional, Wiltshire, D., additional, Wiseman, T., additional, Wolf, P., additional, Wu, K., additional, Yamada, K., additional, Yang, H., additional, Yi, L., additional, Yue, X., additional, Yvon, D., additional, Zilhão, M., additional, Zimmerman, A., additional, and Zumalacarregui, M., additional

Published
2020
Full Text
View/download PDF

31. Creating accurate reference segmentations of deep GM structures in MS patients by fast semi-automated outlining

Author

Sitter, A., Bartel, F., Palotai, M., Burggraaff, J., Liu, Y., Simoes, J., Ruggieri, S., Schregel, K., Pinzon, A. Morales, Ropele, S., Rocca, M. A., Gasperini, C., Gallo, A., Schoonheimm, M., Amann, M., Yiannakas, M., Wattjes, M. P., Sastre-Garriga, J., Kappos, L., Massimo Filippi, Enzinger, C., Ciccarelli, O., Frederiksen, J., Barkhof, F., Guttmann, C. R. G., Munck, J. C., Vrenken, H., Radiology and nuclear medicine, Amsterdam Neuroscience - Brain Imaging, Neurology, Medical psychology, Other Research, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Neuroinfection & -inflammation, CCA - Cancer biology and immunology, and Amsterdam Neuroscience - Neurovascular Disorders

Published
2018

33. Epidemiology of neuromyelitis optica spectrum disorders in Catalonia: a population-based study

Author

Sepulveda, M, Aldea, M, Escudero, D, Llufriu, S, Arrambide, G, Otero-Romero, S, Sastre-Garriga, J, Romero-Pinel, L, Martinez-Yelamos, S, Sola-Valls, N, Armangue, T, Sotoca, J, Escartin, A, Robles, R, Ramio-Torrenta, L, Presas, S, Ramo, C, Munteis, E, Pelayo, R, Gubieras, L, Brieva, L, Ortiz, N, Hervas, M, Mane-Martinez, MA, Cano, A, Vela, E, Tintore, M, Blanco, Y, Montalban, X, Graus, F, and Saiz, A

Published
2017

34. EAN guideline on palliative care of people with severe, progressive multiple sclerosis.

Author

Solari, A., Giordano, A., Sastre‐Garriga, J., Köpke, S., Rahn, A. C., Kleiter, I., Aleksovska, K., Battaglia, M. A., Bay, J., Copetti, M., Drulovic, J., Kooij, L., Mens, J., Meza Murillo, E. R., Milanov, I., Milo, R., Pekmezovic, T., Vosburgh, J., Silber, E., and Veronese, S.

Subjects
PALLIATIVE treatment, MULTIPLE sclerosis, MEDICAL personnel, CARE of people, SYMPTOMS
Abstract

Background and purpose: Patients with severe, progressive multiple sclerosis (MS) have complex physical and psychosocial needs, typically over several years. Few treatment options are available to prevent or delay further clinical worsening in this population. The objective was to develop an evidence‐based clinical practice guideline for the palliative care of patients with severe, progressive MS. Methods: This guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation methodology. Formulation of the clinical questions was performed in the Patients–Intervention–Comparator–Outcome format, involving patients, carers and healthcare professionals (HPs). No uniform definition of severe MS exists: in this guideline, constant bilateral support required to walk 20 m without resting (Expanded Disability Status Scale score > 6.0) or higher disability is referred to. When evidence was lacking for this population, recommendations were formulated using indirect evidence or good practice statements were devised. Results: Ten clinical questions were formulated. They encompassed general and specialist palliative care, advance care planning, discussing with HPs the patient's wish to hasten death, symptom management, multidisciplinary rehabilitation, interventions for caregivers and interventions for HPs. A total of 34 recommendations (33 weak, 1 strong) and seven good practice statements were devised. Conclusions: The provision of home‐based palliative care (either general or specialist) is recommended with weak strength for patients with severe, progressive MS. Further research on the integration of palliative care and MS care is needed. Areas that currently lack evidence of efficacy in this population include advance care planning, the management of symptoms such as fatigue and mood problems, and interventions for caregivers and HPs. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

35. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis

Author

Köpke, S., primary, Giordano, A., additional, Veronese, S., additional, Rahn, A. C., additional, Kleiter, I., additional, Basedow‐Rajwich, B., additional, Fornari, A., additional, Battaglia, M. A., additional, Drulovic, J., additional, Kooij, L., additional, Koops, J., additional, Mens, J., additional, Meza Murillo, E. R., additional, Milanov, I., additional, Milo, R., additional, Patti, F., additional, Pekmezovic, T., additional, Sastre‐Garriga, J., additional, Vosburgh, J., additional, Voltz, R., additional, Bay, J., additional, Oliver, D. J., additional, and Solari, A., additional

Published
2018
Full Text
View/download PDF

37. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

Author

Sepúlveda, Maria, primary, Aldea, Marta, additional, Escudero, Domingo, additional, Llufriu, Sara, additional, Arrambide, Georgina, additional, Otero-Romero, Susana, additional, Sastre-Garriga, J, additional, Romero-Pinel, Lucía, additional, Martínez-Yélamos, Sergio, additional, Sola-Valls, N, additional, Armangué, Thais, additional, Sotoca, Javier, additional, Escartín, Antonio, additional, Robles-Cedeño, René, additional, Ramió-Torrentà, Lluís, additional, Presas-Rodríguez, Silvia, additional, Ramo-Tello, Cristina, additional, Munteis, Elvira, additional, Pelayo, Raúl, additional, Gubieras, Laura, additional, Brieva, Luis, additional, Ortiz, Nicolau, additional, Hervás, Mariona, additional, Mañé-Martínez, Maria Alba, additional, Cano, Antonio, additional, Vela, Emili, additional, Tintoré, Mar, additional, Blanco, Yolanda, additional, Montalban, Xavier, additional, Graus, Francesc, additional, and Saiz, Albert, additional

Published
2017
Full Text
View/download PDF

42. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis.

Author

Köpke, S., Giordano, A., Veronese, S., Christin Rahn, A., Kleiter, I., Basedow‐Rajwich, B., Fornari, A., Battaglia, M. A., Drulovic, J., Kooij, L., Koops, J., Mens, J., Meza Murillo, E. R., Milanov, I., Milo, R., Patti, F., Pekmezovic, T., Sastre‐Garriga, J., Vosburgh, J., and Voltz, R.

Subjects
MULTIPLE sclerosis, PALLIATIVE treatment, MEDICAL rehabilitation, CAREGIVERS, INTERNET surveys
Abstract

Background and purpose: Patient and public involvement in clinical practice guideline development is recommended to increase guideline trustworthiness and relevance. The aim was to engage multiple sclerosis (MS) patients and caregivers in the definition of the key questions to be answered in the European Academy of Neurology guideline on palliative care of people with severe MS. Methods: A mixed methods approach was used: an international online survey launched by the national MS societies of eight countries, after pilot testing/debriefing on 20 MS patients and 18 caregivers, focus group meetings of Italian and German MS patients and caregivers. Results: Of 1199 participants, 951 (79%) completed the whole online survey and 934 from seven countries were analysed: 751 (80%) were MS patients (74% women, mean age 46.1) and 183 (20%) were caregivers (36% spouses/partners, 72% women, mean age 47.4). Participants agreed/strongly agreed on inclusion of the nine pre‐specified topics (from 89% for 'advance care planning' to 98% for 'multidisciplinary rehabilitation'), and <5% replied 'I prefer not to answer' to any topic. There were 569 free comments: 182 (32%) on the pre‐specified topics, 227 (40%) on additional topics (16 guideline‐pertinent) and 160 (28%) on outcomes. Five focus group meetings (three of MS patients, two of caregivers, and overall 35 participants) corroborated the survey findings. In addition, they allowed an explanation of the guideline production process and the exploration of patient‐important outcomes and of taxing issues. Conclusions: Multiple sclerosis patient and caregiver involvement was resource and time intensive, but rewarding. It was the key for the formulation of the 10 guideline questions and for the identification of patient‐important outcomes. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.

Author

Sepúlveda, Maria, Aldea, Marta, Escudero, Domingo, Llufriu, Sara, Arrambide, Georgina, Otero-Romero, Susana, Sastre-Garriga, J., Romero-Pinel, Lucía, Martínez-Yélamos, Sergio, Sola-Valls, N., Armangué, Thais, Sotoca, Javier, Escartín, Antonio, Robles-Cedeño, René, Ramió-Torrentà, Lluís, Presas-Rodríguez, Silvia, Ramo-Tello, Cristina, Munteis, Elvira, Pelayo, Raúl, and Gubieras, Laura

Subjects
NEUROMYELITIS optica, MYELIN oligodendrocyte glycoprotein, DEMYELINATION, IMMUNOGLOBULINS, AQUAPORINS
Abstract

Background: Population-based studies on neuromyelitis optica spectrum disorders (NMOSD) are limited, and it is unclear whether the rates have changed with the implementation of the new 2015 criteria. Objectives: To estimate the incidence and prevalence of NMOSD in Catalonia (Spain), using both the 2006 and the 2015 criteria. Methods: In this clinic-based retrospective study, patients diagnosed with NMOSD between 2006 and 2015 were identified using multiple sources, including direct contact to all Catalan hospitals, identification of cases through the Catalan Health Surveillance System, and registry of antibodies to aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) in a reference laboratory. The incidence rate was calculated for the period 1 January 2006–1 January 2016 and prevalence for the date 1 January 2016. Results: We identified 74 patients (by the 2015 criteria). Most patients were Caucasian (81%), and female (76%) with a median age at disease onset of 42 years (range, 10–76 years). In total, 54 (73%) patients were positive for AQP4-IgG, 11 (15%) double-seronegative, and 9 (12%) MOG-IgG-positive. Rates of incidence and prevalence (0.63/1,000,000 person-years and 0.89/100,000, respectively) were 1.5-fold higher than those reported by the 2006 criteria. Lowest rates were seen in children and elder people and highest in women and middle-aged people (40–59 years). The female predominance was lost in incident AQP4-IgG-seronegative children and AQP4-IgG-positive elder people. MOG-IgG and double-seronegativity contributed similarly but did not influence the long-term outcome. Conclusion: The new criteria increase the estimates, but NMOSD remains as a rare disease. The differences in age- and sex-specific estimates highlight the importance of the serologic classification. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

46. Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe

Author

Otero-Romero, S., primary, Ramió-Torrentà, Ll., additional, Pericot, I., additional, Carmona, O., additional, Perkal, H., additional, Saiz, A., additional, Bufill, E., additional, Robles, R., additional, Simón, E., additional, Llufriu, S., additional, Vaqué-Rafart, J., additional, Sastre-Garriga, J., additional, and Montalban, X., additional

Published
2015
Full Text
View/download PDF

49. Significant clinical worsening after natalizumab withdrawal: Predictive factors

Author

Vidal-Jordana, A, primary, Tintoré, M, additional, Tur, C, additional, Pérez-Miralles, F, additional, Auger, C, additional, Río, J, additional, Nos, C, additional, Arrambide, G, additional, Comabella, M, additional, Galán, I, additional, Castilló, J, additional, Sastre-Garriga, J, additional, Rovira, A, additional, and Montalban, X, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results